Docusign Inc (NASDAQ:DOCU) Director Sells $27,899,728.64 in Stock

Docusign Inc (NASDAQ:DOCU) Director Peter Solvik sold 541,532 shares of the stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $51.52, for a total value of $27,899,728.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of DOCU opened at $53.20 on Friday. Docusign Inc has a 12 month low of $35.06 and a 12 month high of $68.35. The firm’s fifty day simple moving average is $51.95. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market cap of $9.35 billion, a price-to-earnings ratio of -18.34 and a beta of 1.30.

Docusign (NASDAQ:DOCU) last issued its quarterly earnings data on Thursday, June 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.30. Docusign had a negative return on equity of 22.27% and a negative net margin of 26.54%. The firm had revenue of $213.96 million during the quarter, compared to analyst estimates of $208.15 million. During the same quarter in the prior year, the business posted $0.01 EPS. The business’s revenue for the quarter was up 37.3% compared to the same quarter last year. Research analysts forecast that Docusign Inc will post -0.99 earnings per share for the current fiscal year.

Several analysts have issued reports on DOCU shares. Wedbush set a $17.00 target price on Zumiez and gave the company a “sell” rating in a research report on Friday, June 7th. FBN Securities initiated coverage on Docusign in a report on Tuesday, July 9th. They set an “outperform” rating and a $60.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Vail Resorts in a report on Friday, June 7th. Finally, ValuEngine upgraded Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $61.36.

A number of hedge funds have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY raised its stake in Docusign by 4.2% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 5,896 shares of the company’s stock worth $305,000 after acquiring an additional 237 shares during the last quarter. Piedmont Investment Advisors Inc. raised its stake in Docusign by 5.3% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 5,624 shares of the company’s stock worth $292,000 after acquiring an additional 282 shares during the last quarter. Valeo Financial Advisors LLC raised its stake in Docusign by 11.3% in the 1st quarter. Valeo Financial Advisors LLC now owns 3,300 shares of the company’s stock worth $171,000 after acquiring an additional 335 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in Docusign by 12.8% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 4,384 shares of the company’s stock worth $227,000 after acquiring an additional 498 shares during the last quarter. Finally, Sonora Investment Management LLC purchased a new position in Docusign in the 1st quarter worth $31,000. Institutional investors own 61.15% of the company’s stock.

Docusign Company Profile

DocuSign, Inc provides cloud based software in the United States. The company offers e-signature solution that enables businesses to digitally prepare, execute, and act on agreements. The company sells its products through direct, partner-assisted, and Web-based sales. It serves enterprise businesses, commercial businesses, and small businesses, such as professionals, sole proprietorships and individuals.

Read More: Understanding the two types of arbitrage

Insider Buying and Selling by Quarter for Docusign (NASDAQ:DOCU)

Receive News & Ratings for Docusign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Docusign and related companies with MarketBeat.com's FREE daily email newsletter.